Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes between control and C1orf112-knockout (KO) human multiple myeloma (MM) cell lines

ABSTRACT: Gene expression changes between control and C1orf112-knockout (KO) human multiple myeloma (MM) cell lines

PROVIDER: PRJNA927033 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression changes between control and C1orf112-knockout (KO) human multiple myeloma (MM) cell lines

Project description:To examine the effect of C1orf112 disruption on the gene expression changes in MM cells , we generated C1orf112-KO cells with KMS-11, OPM-2, and ANBL-6 cells. The control and C1orf112-KO MM cells were incubated for 48 h in the typical cell culture medium.

2023-06-01 | GSE223650 | GEO

Expression data from control-knockout (CTR-KO) and MIF-KO human multiple myeloma (MM) cells

Project description:Macophage migration inhibitor (MIF) is important for MM resistance to proteasome inhibitors. To determine what signalling pathways are affected by MIF in MM cells, we established MIF-KO MM.1S and ARP-1 MM cell lines. Total RNAs of 2 x 106 CTR-KO and MIF-KO MM cells were extracted by RNeasy Mini Kit (Qiagen). 5-10 µg RNA samples were sent to Gene Expression and Genotyping Facility at Case Western Reserve University (Cleveland, OH) for RNA-seq followed by data analysis. We use microarray data to determine differential expression of genes in MIF-KO and CTR-KO MM cells.

2020-05-07 | GSE141170 | GEO

Expression data from control-knockout (CTR-KO) and MIF-KO human multiple myeloma (MM) cells

Project description:Expression data from control-knockout (CTR-KO) and MIF-KO human multiple myeloma (MM) cells

| PRJNA592531 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes in Wild Type or BMI1-KO Macrophages (MΦs) and Multiple Myeloma-Associated Macrophages (MM-MΦs)

Project description:Multiple myeloma (MM) is an aggressive malignancy characterized by terminally differentiated plasma cells accumulation in the bone marrow (BM). MM BM exhibits elevated MΦs (macrophages) numbers relative to healthy BM. Here, we found that BMI1 modulates the pro-myeloma functions of MM-MΦs. We generated MΦs and MM-MΦs in vitro from wild type and BMI1-KO mice bone marrow. Total RNA was extracted using TRI reagent (MRC, Cat No.TR 118,USA) from flow sorted CD11b+ F4/80+ cells from murine BM-derived MΦs and MM-MΦs. Libraries were prepared using the VAHTSTM total RNA-seq library prep Kit for IIumina (Vazyme, Cat No. NR603, China). RNA-seq was performed by GENEWIZ (Suzhou, China) on an Illumina Hiseq platform.

2021-06-10 | GSE176463 | GEO

MAQC-II Project: Multiple myeloma (MM) data set

Project description:The multiple myeloma (MM) data set (endpoints F, G, H, and I) was contributed by the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS, Little Rock, AR, USA). Gene expression profiling of highly purified bone marrow plasma cells was performed in newly diagnosed patients with MM. The training set consisted of 340 cases enrolled on total therapy 2 (TT2) and the validation set comprised 214 patients enrolled in total therapy 3 (TT3). Plasma cells were enriched by anti-CD138 immunomagnetic bead selection of mononuclear cell fractions of bone marrow aspirates in a central laboratory. All samples applied to the microarray contained more than 85% plasma cells as determined by 2-color flow cytometry (CD38+ and CD45-/dim) performed after selection. Dichotomized overall survival (OS) and eventfree survival (EFS) were determined based on a two-year milestone cutoff. A gene expression model of high-risk multiple myeloma was developed and validated by the data provider and later on validated in three additional independent data sets.

2010-09-11 | GSE24080 | GEO

Gene expression signatures in FAM46C (TENT5C)-deleted multiple myeloma (MM) cell lines

Project description:To investigate the effect of FAM46C disruption on gene expression, we generated FAM46C-knockout (FAM46C-KO) cell clones using CRISPR/Cas9 system with MM cell lines OCI-My5, KMS-11, and ANBL-6. Using the generated cell clones, we have employed whole genome microarray expression profiling as a discovery platform to identify genes that are associated with FAM46C expression in MM cell lines. OCI-My5, KMS-11, and ANBL-6 cell clones were cultured for 48 h in vitro.

2018-09-05 | GSE119451 | GEO

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [WES]

Project description:Multiple Myeloma (MM) is a neoplasm of plasma cells originating in the bone marrow and is the second most common blood cancer in the United States. One challenge in understanding the pathogenesis of Multiple Myeloma (MM) and improving treatment is a lack of immunocompetent mouse models. We previously developed the IL6Myc mouse that generates plasmacytomas at 100% frequency that phenotypically resemble aggressive MM. Using comprehensive genomic analysis, we found that the RNA expression patterns between tumors were somewhat heterogenous, but nonetheless resembled MMSET (multiple myeloma SET domain), an aggressive form of human myeloma with poor prognosis. Cell lines derived from the mouse tumors expressed cell-surface markers typical of MM, but also expressed BAFF-R, which is infrequently found in human MM. The cell lines also had heterogeneous responses to chemotherapeutic drugs typically used to treat human MM. Interestingly IL6Myc tumors accumulated variants in genes like those seen in human MM, as well as recurrent Ig translocations, a common characteristic of human MM. These data indicate that the IL6Myc model is a useful model for aggressive MM that can be used to develop treatment and understand how early myc expression influences disease etiology.

2023-12-06 | GSE220827 | GEO

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [tumor RNA-seq]

2023-12-06 | GSE220825 | GEO

Transcription profiling of human U266, MM.1s, KMS11, 8226/S multiple myeloma cell lines treated with arsenic

Project description:We used microarrays to examine changes in gene expression in multiple myeloma cell lines following treatment with arsenic trioxide and darinaparsin Experiment Overall Design: Four multiple myeloma cell lines (U266, MM.1s, KMS11, 8226/S) were treated with either arsenic trioxide (ATO) for 6, 24, or 48 hours or darinaparsin (DAR) for 6 or 24 hours; RNA was extracted from treated and control cells for microarray analysis

2009-02-01 | E-GEOD-14519 | biostudies-arrayexpress

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [cell line RNA-seq]

2023-12-06 | GSE220823 | GEO